Reference number of the aid programme: SA.41471(2015/X) Purpose of public aid: Article 25 of EC Regulation No 651/2014 of 17 June 2014 declaring certain types of aid compatible with the internal market in the application of Articles 107 and 108 of the Treaty (OJ L. I'm sorry. EU L 187/1 of 26.06.2014). Immune-mediated diseases affect millions of people worldwide. Their chronic nature makes them difficult to heal, often threatening the lives of the patients. Activity of the JAK/STAT route plays a major role in the etiology of inflammatory diseases. The aim of the project is to create a drug for the treatment of inflammatory diseases, such as psoriasis, rheumatoid arthritis, non-specific bowel inflammation, lupus. CPL409116 is a JAK1/3 kinase inhibitor, selective to JAK2, whose activity has been demonstrated in biochemical, cellular and imikwomod-induced psoriasis model in mice. The desired effect of inhibiting cytokine secretion by immune cells, e.g. in PBMC isolated peripheral blood tests, suggests the effectiveness of the compound in other immune-mediated diseases. The good bioavailability demonstrated in pharmacokinetic studies entitles the candidate to develop as an oral drug. The applicant plans to develop an inhibitor in several phases of the project. In stage I, the tasks focus on the synthesis of the compound (laboratory, semi-technical and GMP regime) and analytical work related to the characteristics of physico-chemical properties and the determination of analytical methods. In parallel stage II, the applicant plans to prove the effectiveness of the compound in animal models of the above-mentioned diseases and to carry out in vitro (biochemical and cellular) safety tests. The planned stage III is toxicology on two animal species, and its positive completion will allow for the completion of Phase I and II clinical trials foreseen in stage IV of the project.